Cooper Matthew L, Adami Hans-Olov, Grönberg Henrik, Wiklund Fredrik, Green Fiona R, Rayman Margaret P
Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Cancer Res. 2008 Dec 15;68(24):10171-7. doi: 10.1158/0008-5472.CAN-08-1827.
Selenium may affect prostate cancer risk via its plasma carrier selenoprotein P which shows dramatically reduced expression in prostate cancer tumors and cell lines. The selenoprotein P (SEPP1) Ala234 single nucleotide polymorphism (SNP) allele is associated with lower plasma selenoprotein P in men, reducing the concentration/activity of other antioxidant selenoproteins. Selenium status also modifies the effect of the mitochondrial superoxide dismutase (SOD2) SNP Ala16Val on prostate cancer risk. We investigated the relationship of these SNPs with prostate cancer risk. DNA from 2,975 cases and 1,896 age-matched controls from the population-based Prostate Cancer in Sweden study were genotyped using TaqMan assays. Cases were designated aggressive or nonaggressive prostate cancers at diagnosis by clinical criteria. Association with prostate cancer was investigated by logistic regression; gene-gene interaction using a general linear model. The mean plasma selenium concentration measured in 169 controls was relatively low (76.0 +/- 17.2 microg/L). SNP genotype distributions were in Hardy-Weinberg equilibrium. SOD2-Ala16+ men were at a greater risk of prostate cancer [odds ratios (OR), 1.19; 95% confidence intervals (CI), 1.03-1.37] compared with SOD2-Val16 homozygotes. Men homozygous for SEPP1-Ala234 who were also SOD2-Ala16+ had a higher risk of prostate cancer (OR, 1.43; 95% CI, 1.17-1.76) and aggressive prostate cancer (OR, 1.60; 95% CI, 1.22-2.09) than those who were SOD2-Val16 homozygotes (interaction, prostate cancer P = 0.05; aggressive prostate cancer P = 0.01). This interaction was stronger in ever-smokers: SOD2-Ala16+ men homozygous for SEPP1-Ala234 had an almost doubled risk of prostate cancer (OR, 1.97; 95% CI, 1.33-2.91; interaction P = 0.001). In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.
硒可能通过其血浆载体硒蛋白P影响前列腺癌风险,硒蛋白P在前列腺癌肿瘤和细胞系中的表达显著降低。硒蛋白P(SEPP1)Ala234单核苷酸多态性(SNP)等位基因与男性较低的血浆硒蛋白P相关,降低了其他抗氧化硒蛋白的浓度/活性。硒状态还会改变线粒体超氧化物歧化酶(SOD2)SNP Ala16Val对前列腺癌风险的影响。我们研究了这些SNP与前列腺癌风险的关系。使用TaqMan分析对来自瑞典基于人群的前列腺癌研究中的2975例病例和1896例年龄匹配对照的DNA进行基因分型。根据临床标准,病例在诊断时被指定为侵袭性或非侵袭性前列腺癌。通过逻辑回归研究与前列腺癌的关联;使用一般线性模型研究基因-基因相互作用。在169名对照中测得的平均血浆硒浓度相对较低(76.0±17.2微克/升)。SNP基因型分布符合哈迪-温伯格平衡。与SOD2-Val16纯合子相比,SOD2-Ala16+男性患前列腺癌的风险更高[比值比(OR)为1.19;95%置信区间(CI)为1.03-1.37]。SEPP1-Ala234纯合且也是SOD2-Ala16+的男性患前列腺癌(OR为1.43;95%CI为1.17-1.76)和侵袭性前列腺癌(OR为1.60;95%CI为1.22-2.09)的风险高于SOD2-Val16纯合子(相互作用,前列腺癌P=0.05;侵袭性前列腺癌P=0.01)。这种相互作用在曾经吸烟者中更强:SEPP1-Ala234纯合的SOD2-Ala16+男性患前列腺癌的风险几乎加倍(OR为1.97;95%CI为1.33-2.91;相互作用P=0.001)。在低硒人群中,SEPP1-Ala234纯合的SOD2-Ala16+男性患前列腺癌/侵袭性前列腺癌的风险增加,尤其是曾经吸烟者,因为他们可能产生更多无法清除的线粒体过氧化氢,从而促进前列腺肿瘤细胞的增殖和迁移。